Bulletin du Cancer
MENUNews about... the proteasome inhibitor PS341 Volume 89, issue 1, Janvier 2002
Author
CNRS-Inserm, Institut de signalisation, Biologie du développement et cancer, parc Valrose, 06108 Nice Cedex 2.
- Key words: PS341, proteasome inhibitor.
- Page(s) : 29-30
- Published in: 2002
The proteasome degradation system is one of the most efficient proteolytic process in living cells. We will focus here on a new compound, called PS341, which is the first proteasome inhibitor entering clinical phases. First results about its use in multiple myeloma or leukemic cells will be discussed.